Product Description
Mechanisms of Action: TLR9 Inhibitor,STAT3 Inhibitor
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: City of Hope Medical Center
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Diffuse Large B-Cell Lymphoma|Lymphoma, Non-Hodgkin|Follicular Lymphoma|Mantle-Cell Lymphoma|B-Cell Marginal Zone Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCI-2021-06965 | P1 |
Withdrawn |
Chronic Lymphoid Leukemia|Follicular Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Diffuse Large B-Cell Lymphoma|Mantle-Cell Lymphoma|Lymphoma, Non-Hodgkin|B-Cell Marginal Zone Lymphoma |
2024-01-04 |